相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hydroxyureas as Noncovalent Proteasome Inhibitors
Nerea Gallastegui et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
H. Travis Ichikawa et al.
ARTHRITIS AND RHEUMATISM (2012)
Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
Eva M. Huber et al.
CELL (2012)
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development
Melissa Ann Graewert et al.
CHEMICAL COMMUNICATIONS (2012)
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Alexei F. Kisselev et al.
CHEMISTRY & BIOLOGY (2012)
Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer
Susan M. Molineaux
CLINICAL CANCER RESEARCH (2012)
The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
Kenneth C. Anderson
JOURNAL OF CLINICAL ONCOLOGY (2012)
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells
N. E. Franke et al.
LEUKEMIA (2012)
Mice completely lacking immunoproteasomes show major changes in antigen presentation
Eleanor Z. Kincaid et al.
NATURE IMMUNOLOGY (2012)
Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis
Sue Ellen Verbrugge et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Elucidation of the alpha-Keto-Aldehyde Binding Mechanism: A Lead Structure Motif for Proteasome Inhibition
Melissa Ann Graewert et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
Ajita V. Singh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib
Anne C. Mirabella et al.
CHEMISTRY & BIOLOGY (2011)
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Shirin Arastu-Kapur et al.
CLINICAL CANCER RESEARCH (2011)
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
D. J. Kuhn et al.
CURRENT CANCER DRUG TARGETS (2011)
Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
B. C. Potts et al.
CURRENT CANCER DRUG TARGETS (2011)
Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Michael Groll et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
The Immunoproteasome: An Emerging Therapeutic Target
Wooin Lee et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
The Antiviral Immune Response in Mice Devoid of Immunoproteasome Activity
Michael Basler et al.
JOURNAL OF IMMUNOLOGY (2011)
Novel Proteasome Inhibitors to Overcome Bortezomib Resistance
Amy M. Ruschak et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells
Erika Suzuki et al.
PLOS ONE (2011)
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit
Christopher Blackburn et al.
BIOCHEMICAL JOURNAL (2010)
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
Dharminder Chauhan et al.
BLOOD (2010)
Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Erik Kupperman et al.
CANCER RESEARCH (2010)
Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress
Ulrike Seifert et al.
CELL (2010)
20S Proteasome Inhibition: Designing Noncovalent Linear Peptide Mimics of the Natural Product TMC-95A
Michael Groll et al.
CHEMMEDCHEM (2010)
Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
E. Genin et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2010)
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Lawrence R. Dick et al.
DRUG DISCOVERY TODAY (2010)
Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors
Michael Screen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome
Michael Basler et al.
JOURNAL OF IMMUNOLOGY (2010)
Molecular Basis of the Selectivity of the Immunoproteasome Catalytic Subunit LMP2-Specific Inhibitor Revealed by Molecular Modeling and Dynamics Simulations
Beilei Lei et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2010)
Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma
Paul G. Richardson
LANCET ONCOLOGY (2010)
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
M. Ri et al.
LEUKEMIA (2010)
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies
Guido Cavaletti et al.
LEUKEMIA & LYMPHOMA (2010)
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC)
Tianhong Li et al.
LUNG CANCER (2010)
Bortezomib in Kidney Transplantation
Rajeev Raghavan et al.
JOURNAL OF TRANSPLANTATION (2010)
Proteasomes in immune cells: more than peptide producers?
Marcus Groettrup et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Daniel Finley
ANNUAL REVIEW OF BIOCHEMISTRY (2009)
Cardiovascular Inflammation and Lesion Cell Apoptosis A Novel Connection via the Interferon-Inducible Immunoproteasome
Zhaoqing Yang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Deborah J. Kuhn et al.
BLOOD (2009)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents
Takashi Takeshita et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites
Matthew Britton et al.
CHEMISTRY & BIOLOGY (2009)
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
Shuqing Lue et al.
EXPERIMENTAL HEMATOLOGY (2009)
Expression of catalytic proteasome subunits in the gut of patients with Crohn's disease
Alexander Visekruna et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
Function-Oriented Biosynthesis of β-Lactone Proteasome Inhibitors in Salinispora tropica
Markus Nett et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
Han-Jie Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
D. Gutman et al.
LEUKEMIA (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
Many facets of bortezomib resistance/susceptibility
Shaji Kumar et al.
BLOOD (2008)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Argyrin A reveals a critical role for the tumor suppressor protein p27kip1 in mediating antitumor activities in response to proteasome inhibition
Irina Nickeleit et al.
CANCER CELL (2008)
Thymoproteasome: probable role in generating positively selecting peptides
Shigeo Murata et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Mechanisms of proteasome inhibitor action and resistance in cancer
David J. McConkey et al.
DRUG RESISTANCE UPDATES (2008)
Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates
Gang Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism
Michael Groll et al.
NATURE (2008)
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
Roberto Piva et al.
BLOOD (2008)
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
Angela M. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Enhanced expression of interferon-γ-induced antigen-processing machinery components in a spontaneously occurring cancer
Fulvia Cerruti et al.
NEOPLASIA (2007)
Bortezomib for the treatment of mantle cell lymphoma
Robert C. Kane et al.
CLINICAL CANCER RESEARCH (2007)
Assessing the role of immuno-proteasomes in a mouse model of familial ALS
Krishna Puttaparthi et al.
EXPERIMENTAL NEUROLOGY (2007)
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells
Claudia P. Miller et al.
BLOOD (2007)
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status
Hans Minderman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors
Jens Voortman et al.
CLINICAL CANCER RESEARCH (2007)
Regulation of CD8+ T cell development by thymus-specific proteasomes
Shigeo Murata et al.
SCIENCE (2007)
LMP2-specific inhibitors: Chemical genetic tools for proteasome biology
Yik Khuan (Abby) Ho et al.
CHEMISTRY & BIOLOGY (2007)
Transformation of the proteasome with age-related macular degeneration
Cheryl M. Ethen et al.
FEBS LETTERS (2007)
Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease
Leo R. Fitzpatrick et al.
DISEASES OF THE COLON & RECTUM (2007)
Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat
Guido Cavaletti et al.
EXPERIMENTAL NEUROLOGY (2007)
20S proteasome and its inhibitors: Crystallographic knowledge for drug development
Ljudmila Borissenko et al.
CHEMICAL REVIEWS (2007)
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
Mark J. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice
Leo R. Fitzpatrick et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132
Lisa J. A. Crawford et al.
CANCER RESEARCH (2006)
United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy
Robert C. Kane et al.
CLINICAL CANCER RESEARCH (2006)
Tissue-specific up-regulation of the proteasome subunit β5i (LMP7) in Sjogren's syndrome
Thomas Egerer et al.
ARTHRITIS AND RHEUMATISM (2006)
Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis
M Bazzaro et al.
CANCER RESEARCH (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains
M Mishto et al.
NEUROBIOLOGY OF AGING (2006)
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells
ST Nawrocki et al.
CANCER RESEARCH (2005)
Non-neuronal induction of immunoproteasome subunits in an ALS model: Possible mediation by cytokines
K Puttaparthi et al.
EXPERIMENTAL NEUROLOGY (2005)
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies
G Jackson et al.
CANCER TREATMENT REVIEWS (2005)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Proteasornal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis
I Ferrer et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2004)
Proteasome and peptidase function in MHC-class-I-mediated antigen presentation
PM Kloetzel et al.
CURRENT OPINION IN IMMUNOLOGY (2004)
Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII
PM Kloetzel
NATURE IMMUNOLOGY (2004)
Approval summary for bortezomib for injection in the treatment of multiple myeloma
PF Bross et al.
CLINICAL CANCER RESEARCH (2004)
A transgenic mouse model of the ubiquitin/proteasome system
K Lindsten et al.
NATURE BIOTECHNOLOGY (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues
IA York et al.
NATURE IMMUNOLOGY (2002)
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
RZ Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The structure of the mammalian 20S proteasome at 2.75 Å resolution
M Unno et al.
STRUCTURE (2002)
Crystal structure of the 20 S proteasome: TMC-95A complex: A non-covalent proteasome inhibitor
M Groll et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
Strategies for the inhibition of serine proteases
B Walker et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2001)
Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093 -: Taxonomy, production, isolation, and biological activities
Y Koguchi et al.
JOURNAL OF ANTIBIOTICS (2000)
分享论文
